The Phase 3 study will assess atacicept vs. placebo on the impact of renal (kidney) function. Safety and patient reported outcomes will be clinically assessed. The clinical study is comprised of a 104 week double-blind treatment period, followed by a 52 week open-label treatment period and a 26 week safety follow-up period. To Learn More …
September 16, 2022 CATEGORIES: Lupus Nephritis First posted September 15, 2022, Updated September 15, 2022 This trial aims to learn about the safety and tolerability of daxdilimab (trial drug), and to learn about the effect it has on lupus nephritis when combined with standard treatment (that is, mycophenolate mofetil [MMF] or mycophenolic acid [MPA] and …
CATEGORIES: Lupus Nephritis First posted November 30, 2021, Updated August 10, 2022; Recruiting This Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of anifrolumab versus placebo as added to SOC (consisting of MMF and glucocorticoids) in adults with active proliferative Class III or Class IV LN (both with or …
First posted September, 2020, Updated September, 2021; Recruiting CATEGORIES: Lupus Nephritis The objectives of this Phase 2, Double-Blind, Randomized, Placebo-Controlled Study is to evaluate the efficacy and safety of ravulizumab in adult participants With proliferative lupus nephritis (LN) or immunoglobulin A nephropathy (IgAN) To Learn More Contact Contact: Alexion Pharmaceuticals, Inc.at 855-752-2356 or clinicaltrials@alexion.com ClinicalTrials.gov identifier: …
The purpose of this trial is to evaluate the efficacy and safety of subcutaneous secukinumab 300 mg compared to placebo, in combination with standard of care therapy (SoC), in subjects with active lupus nephritis (ISN/RPS Class III or IV, with or without co-existing class V features). To Learn More Contact Novartis Pharmaceuticals at 1-888-669-6682 or …
CATEGORIES: Lupus Nephritis The purpose of this study is to determine if AMG 570 could be a useful therapeutic agent in the current treatment landscape where subjects with systemic lupus erythematosus (SLE) have ongoing disease activity despite treatment with standard of care therapies. To Learn More Contact Reference Study ID Number: CA41705 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. …
This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical activity of itolizumab (EQ001) in subjects with Systemic Lupus Erythematosus with or without Active Proliferative Lupus Nephritis. To Learn More Contact: Study Contact: Catherine Kim, 858 412 5302 or clinicaltrials@equilliumbio.com ClinicalTrials.gov Identifer: NCT04128579 …
CATEGORIES: Lupus Nephritis The purpose of thisPhase 3 study is assess the long-term safety and tolerability of voclosporin compared with placebo for up to an additional 24 months following completion of treatment in the AURORA 1 study in subjects with lupus nephritis (LN). To Learn More Contact GS-US-437-4093@gilead.com ClinicalTrials.gov identifier: NCT03285711 …
First posted July, 2020, Updated November, 2021; Recruiting CATEGORIES: CNS Lupus This research study is being done to test the effects of centrally-acting ACE inhibitor, named lisinopril, on resting metabolism in the brain and on cognitive function. The investigators will see if Lisinopril will decrease resting metabolism in the brain and improve cognitive function (memory …
Use this tool to search all lupus trials and create a personalized list of studies by the type of lupus you have and where you live.
LupusTrials.org